{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T03:00:11Z","timestamp":1791687611972,"version":"4.3.4"},"reference-count":48,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T00:00:00Z","timestamp":1673222400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["worldallergyorganizationjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["World Allergy Organization Journal"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.waojou.2023.100746","type":"journal-article","created":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T20:57:52Z","timestamp":1676408272000},"page":"100746","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["A real-life comparison of pulmonary and nasal outcomes in patients with severe asthma and nasal polyposis treated with T2-biologics"],"prefix":"10.1016","volume":"16","author":[{"given":"Ulrike","family":"F\u00f6rster-Ruhrmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafni","family":"Stergioudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka J.","family":"Szczepek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim W.","family":"Fluhr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Zuberbier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Olze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl-Christian","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10100","key":"10.1016\/j.waojou.2023.100746_bib1","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/S0140-6736(17)32154-2","article-title":"Injury I, Prevalence C. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"390","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.waojou.2023.100746_bib2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/all.14425","article-title":"EAACI Biologicals Guidelines-Recommendations for severe asthma","volume":"76","author":"Agache","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.waojou.2023.100746_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2019.101301","article-title":"Severe asthma phenotypes and endotypes","volume":"46","author":"Agache","year":"2019","journal-title":"Semin Immunol"},{"key":"10.1016\/j.waojou.2023.100746_bib4","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/1471-2458-12-204","article-title":"Global asthma prevalence in adults: findings from the cross-sectional world health survey","volume":"12","author":"To","year":"2012","journal-title":"BMC Publ Health"},{"key":"10.1016\/j.waojou.2023.100746_bib5","series-title":"Global Strategy for Asthma Management and Prevention 2021","year":"2021"},{"issue":"5","key":"10.1016\/j.waojou.2023.100746_bib6","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/all.14221","article-title":"Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma","volume":"75","author":"Agache","year":"2020","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.waojou.2023.100746_bib7","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.waojou.2023.100746_bib8","unstructured":"Bundes\u00e4rztekammer (B\u00c4K), Kassen\u00e4rztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Asthma \u2013 Langfassung, 4. Auflage. Version 1. 2020. DOI: 10.6101\/AZQ\/000469. www.asthma.versorgungsleitlinien.de. Accessed 19 August 2022."},{"issue":"11","key":"10.1016\/j.waojou.2023.100746_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2021.100606","article-title":"Severe asthma: one disease and multiple definitions","volume":"14","author":"Bagnasco","year":"2021","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.waojou.2023.100746_bib10","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2147\/JAA.S321212","article-title":"Association between a type 2 inflammatory disease burden score and outcomes among patients with asthma","volume":"14","author":"Price","year":"2021","journal-title":"J\u00a0Asthma Allergy"},{"issue":"1","key":"10.1016\/j.waojou.2023.100746_bib11","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12931-017-0524-y","article-title":"Cluster analysis of sputum cytokine-high profiles reveals diversity in T(h)2-high asthma patients","volume":"18","author":"Seys","year":"2017","journal-title":"Respir Res"},{"issue":"8 Pt 2","key":"10.1016\/j.waojou.2023.100746_bib12","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1164\/ajrccm.164.supplement_1.2103026","article-title":"Anti-immunoglobulin E (omalizumab) therapy in allergic asthma","volume":"164","author":"Busse","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.waojou.2023.100746_bib13","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1398-9995.2004.00772.x","article-title":"Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): innovate","volume":"60","author":"Humbert","year":"2005","journal-title":"Allergy"},{"issue":"9842","key":"10.1016\/j.waojou.2023.100746_bib14","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.waojou.2023.100746_bib15","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.waojou.2023.100746_bib16","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.waojou.2023.100746_bib17","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respir Med"},{"issue":"10056","key":"10.1016\/j.waojou.2023.100746_bib18","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"issue":"10056","key":"10.1016\/j.waojou.2023.100746_bib19","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.waojou.2023.100746_bib20","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s12325-018-0702-4","article-title":"Liberty asthma QUEST: phase 3 randomized, double-blind, placebo-controlled, parallel-group study to evaluate dupilumab efficacy\/safety in patients with uncontrolled, moderate-to-severe asthma","volume":"35","author":"Busse","year":"2018","journal-title":"Adv Ther"},{"issue":"2","key":"10.1016\/j.waojou.2023.100746_bib21","doi-asserted-by":"crossref","first-page":"82","DOI":"10.4193\/Rhin20.601","article-title":"Executive summary of EPOS 2020 including integrated care pathways","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"issue":"1","key":"10.1016\/j.waojou.2023.100746_bib22","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaci.2020.11.013","article-title":"EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: definitions and management","volume":"147","author":"Bachert","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"10","key":"10.1016\/j.waojou.2023.100746_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2021.100592","article-title":"ARIA-Italy multidisciplinary consensus on nasal polyposis and biological treatments","volume":"14","author":"Lombardi","year":"2021","journal-title":"World Allergy Organ J"},{"issue":"8","key":"10.1016\/j.waojou.2023.100746_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2019.100050","article-title":"Biologics for the treatment of chronic rhinosinusitis with nasal polyps - state of the art","volume":"12","author":"Ren","year":"2019","journal-title":"World Allergy Organ J"},{"issue":"5","key":"10.1016\/j.waojou.2023.100746_bib25","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.jaci.2015.12.1324","article-title":"Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers","volume":"137","author":"Tomassen","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.waojou.2023.100746_bib26","article-title":"Chemokine expression-based endotype clustering of chronic rhinosinusitis","volume":"12","author":"Forster-Ruhrmann","year":"2022","journal-title":"J\u00a0Personalized Med"},{"issue":"2","key":"10.1016\/j.waojou.2023.100746_bib27","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1067\/mai.2000.108310","article-title":"Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic\u00a0rhinitis","volume":"106","author":"Adelroth","year":"2000","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.waojou.2023.100746_bib28","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jaci.2013.04.052","article-title":"Severe adult-onset asthma: a distinct phenotype","volume":"132","author":"Amelink","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.waojou.2023.100746_bib29","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2147\/JAA.S290424","article-title":"Burden of disease in chronic rhinosinusitis with nasal polyps","volume":"14","author":"Bachert","year":"2021","journal-title":"J\u00a0Asthma Allergy"},{"issue":"5","key":"10.1016\/j.waojou.2023.100746_bib30","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.jaip.2018.10.016","article-title":"The severe asthma network in Italy: findings and perspectives","volume":"7","author":"Heffler","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.waojou.2023.100746_bib31","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.anai.2021.01.012","article-title":"Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma","volume":"126","author":"Laidlaw","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"10.1016\/j.waojou.2023.100746_bib32","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jaci.2003.09.008","article-title":"Development of the asthma control test: a survey for assessing asthma control","volume":"113","author":"Nathan","year":"2004","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.waojou.2023.100746_bib33","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2500\/105065895781808711","article-title":"Psychometric and clinimetric validity of the 31-ltem rhinosinusitis outcome measure (RSOM-31)","volume":"9","author":"Piccirillo","year":"1995","journal-title":"Am J Rhinol"},{"issue":"3","key":"10.1016\/j.waojou.2023.100746_bib34","first-page":"226","article-title":"Omalizumab in patients with NSAIDs-exacerbated respiratory disease","volume":"58","author":"Forster-Ruhrmann","year":"2020","journal-title":"Rhinology"},{"issue":"11","key":"10.1016\/j.waojou.2023.100746_bib35","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1111\/j.1398-9995.2009.02169.x","article-title":"GA2LEN skin test study III: minimum battery of test inhalent allergens needed in epidemiological studies in patients","volume":"64","author":"Bousquet","year":"2009","journal-title":"Allergy"},{"issue":"5","key":"10.1016\/j.waojou.2023.100746_bib36","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1136\/adc.80.5.414","article-title":"Validation of an asthma symptom diary for interventional studies","volume":"80","author":"Santanello","year":"1999","journal-title":"Arch Dis Child"},{"issue":"5","key":"10.1016\/j.waojou.2023.100746_bib37","doi-asserted-by":"crossref","first-page":"573","DOI":"10.23736\/S0026-4806.21.07623-0","article-title":"Monoclonal antibodies in type 2 asthma: an updated network meta-analysis","volume":"112","author":"Edris","year":"2021","journal-title":"Minerva Med"},{"issue":"3","key":"10.1016\/j.waojou.2023.100746_bib38","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00306-2021","article-title":"Indirect comparison of efficacy of dupilumab versus mepolizumab and omalizumab for severe type 2 asthma","volume":"7","author":"Praetorius","year":"2021","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.waojou.2023.100746_bib39","doi-asserted-by":"crossref","first-page":"767","DOI":"10.2147\/JAA.S363527","article-title":"Improvement in health-related quality of life with dupilumab in patients with moderate-to-severe asthma with comorbid chronic rhinosinusitis with\/without nasal polyps: an analysis of the QUEST study","volume":"15","author":"Hopkins","year":"2022","journal-title":"J\u00a0Asthma Allergy"},{"issue":"12","key":"10.1016\/j.waojou.2023.100746_bib40","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1016\/j.jaip.2021.08.004","article-title":"Benralizumab effectiveness in severe eosinophilic asthma with and without chronic rhinosinusitis with nasal polyps: a real-world multicenter study","volume":"9","author":"Nolasco","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.waojou.2023.100746_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial","author":"Han","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"4","key":"10.1016\/j.waojou.2023.100746_bib42","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jaci.2021.08.030","article-title":"Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial","volume":"149","author":"Bachert","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.waojou.2023.100746_bib43","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.waojou.2023.100746_bib44","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/all.13984","article-title":"Dupilumab improves health-related quality of life in patients with chronic rhinosinusitis with nasal polyposis","volume":"75","author":"Bachert","year":"2020","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/j.waojou.2023.100746_bib45","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1159\/000519228","article-title":"Which is the best biologic for nasal polyps: dupilumab, omalizumab, or mepolizumab? A network meta-analysis","volume":"183","author":"Wu","year":"2022","journal-title":"Int Arch Allergy Immunol"},{"issue":"6","key":"10.1016\/j.waojou.2023.100746_bib46","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.jaip.2021.01.031","article-title":"Indirect treatment comparison of biologics in chronic rhinosinusitis with nasal polyps","volume":"9","author":"Peters","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.waojou.2023.100746_bib47","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.jaci.2021.09.009","article-title":"Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: a systematic review and network meta-analysis","volume":"149","author":"Oykhman","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.waojou.2023.100746_bib48","doi-asserted-by":"crossref","DOI":"10.1002\/clt2.12049","article-title":"Real-life effectiveness of biological therapies on symptoms in severe asthma with comorbid CRSwNP","volume":"11","author":"Mummler","year":"2021","journal-title":"Clin Transl Allergy"}],"container-title":["World Allergy Organization Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1939455123000066?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1939455123000066?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T18:45:46Z","timestamp":1761849946000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1939455123000066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S1939455123000066"],"URL":"https:\/\/doi.org\/10.1016\/j.waojou.2023.100746","relation":{},"ISSN":["1939-4551"],"issn-type":[{"value":"1939-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A real-life comparison of pulmonary and nasal outcomes in patients with severe asthma and nasal polyposis treated with T2-biologics","name":"articletitle","label":"Article Title"},{"value":"World Allergy Organization Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.waojou.2023.100746","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc. on behalf of World Allergy Organization.","name":"copyright","label":"Copyright"}],"article-number":"100746"}}